.
3. Aitken, A. et al., Eur. J. Biochem., 139, 663-
671(1984).
4. Yokoyama, N. et al., Arch. Biochem. Biophys., 300,
615-621 (1993).
5. Hashimoto Y. et al., J. Biol. Chem., 265, 1924-1927
16 h
at 4°C in 66 mM Tris-HCl, 5 mM MgCl2, 5 mM Dithioth-
reitol, 1 mM ATP, pH 7.5 (at 20°C) resulting in >95 %
recovery of 1 μg �DNA fragments.
Subsequent re-cutting with Pst I yields > 95%
et al., Cell. 181:281–92.e6 (2020).
3. Shang J., et al., Nature. 581:221–4 (2020).
4. Tai W., et al. Cell Mol Immunol. 17:621–30 (2020).
5. Chen Y., et al., Biochem Biophys Res Commun.
525:135–40
et al., Cell. 181:281–92.e6 (2020).
3. Shang J., et al., Nature. 581:221–4 (2020).
4. Tai W., et al. Cell Mol Immunol. 17:621–30 (2020).
5. Chen Y., et al., Biochem Biophys Res Commun.
525:135–40
myosin expressed in
the retina is a potential candidate for Bardet-Biedl
syndrome. Genomics, 79, 621-624 (2002).
2. Goldman, J.M. et al., Targeting the BCR-ABL
tyrosine kinase in chronic myeloid
myosin expressed in
the retina is a potential candidate for Bardet-Biedl
syndrome. Genomics, 79, 621-624 (2002).
2. Goldman, J.M. et al., Targeting the BCR-ABL
tyrosine kinase in chronic myeloid
myosin expressed in
the retina is a potential candidate for Bardet-Biedl
syndrome. Genomics, 79, 621-624 (2002).
2. Goldman, J.M. et al., Targeting the BCR-ABL
tyrosine kinase in chronic myeloid
2. Schindler, C., and Darnell, J. E., Ann. Rev.
Biochem., 64, 621 (1995)
3. Leaman, D. W., et al., FASEB J., 10, 1578 (1996).
4. Hou, J., Science, 265, 1701 (1994).
5. Ihle, J. N., et al., Ann.